|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.38 / 4.95|
Magnetic Resonance Imaging (MRI) Evidence for Ampion™ cartilage Regeneration
Investors in Ampio Pharmaceuticals Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMPE options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.
- Primary endpoint of OMERACT-OARSI responder rate at 12 weeks achieved statistical significance (p < 0.001)
TheStreet's biotech columnist offers his own report card on biotech stocks.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ampio Pharmaceuticals Inc , where a total of 1,453 contracts have traded so far, representing approximately 145,300 underlying shares. That amounts to about 81.2% of AMPE's average daily trading volume over the past month of 179,045 shares.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
Ampio Pharma (AMPE) stock is sharply lower this afternoon following a phase 3 trial for its osteoarthritis pain treatment.
Ampio Pharmaceuticals (AMPE) shares are up over 10% after the company received Special Protocol Assessment from the FDA.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.